Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02873754
Other study ID # Pro00074576
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2017
Est. completion date July 2017

Study information

Verified date June 2018
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project proposes to evaluate the feasibility, acceptability, and efficacy of a mobile intervention to target smoking-cessation and increase physical activity among low-income persons. The intervention is called Smoking Treatment and Exercise Program for Underserved Populations (STEP UP).


Description:

This pilot project proposes to evaluate the feasibility, acceptability, and efficacy of a mobile intervention to target smoking-cessation and physical activity among low-income persons. The intervention, named Smoking Treatment and Exercise Program for Underserved Populations (STEP UP), combines a smartphone-based contingency-management application (app), which provides monetary reinforcement for smoking abstinence and physical activity, 5 weeks of telephone-based cognitive-behavioral therapy (CBT) to prevent relapse, nicotine replacement pharmacotherapy, and text-messaging to support physical-activity goals. Participants are given a smartphone, a compact carbon-monoxide (CO) monitor, with which recency of smoking can by determined, and a Garmin Vivosmart wristband step-tracker. Twice a day at semi-random intervals, participants are prompted by the app to submit a video of themselves blowing into the CO monitor. Monetary reinforcement is then immediately provided contingent upon a below-threshold CO reading. The app also continuously syncs with the Garmin step-tracker, providing supportive messaging and bonus incentives—namely doubled reinforcement for smoking abstinence among participants who meet personalized daily step goals. The expected outcome of the project is to provide information to evaluate the efficacy of an innovative approach in preparation for a subsequent larger clinical trial that builds upon the capabilities of mHealth technology to reduce the prevalence of smoking among low income smokers.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date July 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- current household income less than twice the federal poverty guidelines (Finer & Henshaw, 2006; for instance, someone from a family of 4 must have a household income less than $48,500 to be eligible)

- currently smoke >10 cigarettes a day

- smoking for at least the past year

- can speak and write fluent conversational English

- are 18-70 years of age

- are willing to make an attempt to quit smoking and increase physical activity

Exclusion Criteria:

- inability to walk

- expected to have unstable medication regimen during the study

- currently receiving non-study behavioral treatment for smoking

- myocardial infarction in the past 6 months

- contraindication to nicotine replacement therapy (NRT) or bupropion with no medical clearance

- exclusive use of other forms of nicotine such as cigars, pipes, e-cigarettes, or chewing tobacco

- current pregnancy

- current imprisonment or psychiatric hospitalization

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Behavioral Counseling
Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
Mobile Contingency Management
Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
Drug:
Bupropion
All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
Transdermal nicotine patch
Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
Nicotine polacrilex
Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
Nicotine lozenge
Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Self-report Prolonged Abstinence From Smoking Participants will be asked to report on smoking since two weeks past quit date. Prolonged abstinence is defined as continued abstinence from smoking beginning at 2 weeks post-quit. 6 month follow up
Primary Number of Participants Whose Prolonged Abstinence is Bio-verified Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence. Prolonged abstinence is defined as continued abstinence from smoking beginning at 2 weeks post-quit. 6 month follow up
Primary Number of Participants Who Self-report Prolonged Abstinence From Smoking Participants will be asked to report on smoking since two weeks past quit date. Prolonged abstinence is defined as continued abstinence from smoking beginning at 2 weeks post-quit. 3 month follow up
Primary Number of Participants Whose Prolonged Abstinence is Bio-verified Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence. Prolonged abstinence is defined as continued abstinence from smoking beginning at 2 weeks post-quit. 3 month follow up
Secondary Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking 7-day point prevalence abstinence is defined as no smoking in the prior 7 days. 6 month follow up
Secondary Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking 30-day point prevalence abstinence is defined as no smoking in the prior 30 days. 6 month follow up
Secondary Number of Participants Who Report 7 Day Point Prevalence Abstinence From Smoking 7-day point prevalence abstinence is defined as no smoking in the prior 7 days. 3 month follow up
Secondary Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking 30-day point prevalence abstinence is defined as no smoking in the prior 30 days. 3 month follow up
Secondary Change in Physical Activity From Baseline to 3-month Follow-up as Measured by the Stanford 7-day Physical Activity Recall (PAR) Scale. Participants will be interviewed about the amount of time spent in light, moderate, and hard physical activity during the past 7 days. Total number of days of moderate and hard exercise in last 7 days will be compared to self-reported values at baseline (i.e., # of days of exercise in past 7 days at 3-month follow-up minus # of days of exercise in past 7 days at baseline). baseline and 3 month follow up
Secondary Change in the Number of Days in Which Smoked Compared to Pre-quit Use Participants will self-report number of days smoked in the past 30 days and this will be compared to self-reported number of days smoked in 30 days prior to quit. 3 month follow up
Secondary Change in Number of Cigarettes Smoked Per Week Compared to Pre-quit Self-reported number of cigarettes smoked each day in past 7 days; this will be compared to self-reported amount smoked in week prior to quit date 3 month follow up
Secondary Number of Quit Smoking Attempts Participants will self-report the number of quit attempts they've had since baseline. 3 month follow up
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02649556 - A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 N/A
Completed NCT03901066 - Smoking Dependence and Periodontitis
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Completed NCT03305978 - Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. N/A
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Active, not recruiting NCT02752022 - Monitoring the Transition From Smoking to E-cigarettes
Completed NCT02901171 - The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT04340830 - The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants N/A
Completed NCT02912000 - TEACH: Technology Evaluation to Address Child Health N/A
Completed NCT02949648 - Electronic Cigarette Use and Quitting in Youth N/A
Completed NCT02945371 - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life N/A
Completed NCT02246114 - Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women N/A
Completed NCT01954407 - Young Adults' Responses to Anti-smoking Messages N/A
Completed NCT02008292 - Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors N/A
Completed NCT01898507 - Nicotine Metabolism and Low Nicotine Cigarettes N/A